Skip to main content
. 2019 Sep 4;2019(9):CD005049. doi: 10.1002/14651858.CD005049.pub5

A‐STAR 2006.

Methods RCT
Placebo‐controlled, single or double‐blind?
Loss to follow‐up reported: no
Participants Symptomatic AF in the previous 6 months
Type: paroxysmal or recent onset 95%, persistent 5% (mean duration: NS). n = 431
Men: 62%
Age (mean): 62 (SD 10) years
Structural heart disease: 69%. LAD: NS. LVEF: NS
Interventions Azimilide 125 mg/day vs placebo
Method of AF cardioversion: 100% spontaneous or pharmacological
Warfarin discretionary
Outcomes At 6 months:
Mortality
Adverse effects
Proarrhythmia
AF recurrence
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Procedure of randomisation not described.
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding (performance bias and detection bias) 
 All outcomes High risk Placebo‐controlled study, but it was not presented as single or double‐blind.
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Few details given on the 61 participants who withdrew from the study.
Selective reporting (reporting bias) Low risk All prespecified outcomes of interest and main outcomes expected were reported.
Other bias Low risk No other bias apparent.